05:05 AM EDT, 10/07/2025 (MT Newswires) -- Novo Nordisk ( NVO ) has laid off numerous workers at its Clayton, North Carolina, site that produces semaglutides used in its weight-loss and diabetes drugs Wegovy and Ozempic, Reuters reported Monday, citing a review of LinkedIn posts.

Affected roles reportedly span manufacturing and support, from quality control to line technicians, with 47 people publicly indicating layoffs or job searches.

Of the total job cuts, about 5,000 positions are slated to be eliminated in Denmark specifically, mainly to fare better against competition, the news outlet reported.

The reductions are part of a planned 9,000 global job cuts, a Novo Nordisk ( NVO ) spokesperson told MT Newswires, adding that it would not give further details out of respect for the employees.

Shares of the company were down 0.7% in recent Tuesday premarket activity.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)